Kedrion's Plasma Treatment Receives Orphan Drug Designation from EMA Kedrion's treatment for aceruloplasminemia has received Orphan Drug Designation from EMA, marking a significant advance for rare disease therapies.

Kedrion's Plasma Treatment Receives Orphan Drug Designation from EMA #Italy #Orphan_Drug #Castelvecchio_Pascoli #Kedrion #Aceruloplasminemia

Kedrion's Plasma-Derived Treatment Receives Orphan Drug Designation for Rare Genetic Disorder Kedrion's innovative plasma-derived therapy has been given Orphan Drug Designation by the EMA, targeting a rare genetic condition known as Aceruloplasminemia.

Kedrion's Plasma-Derived Treatment Receives Orphan Drug Designation for Rare Genetic Disorder #Italy #EMA #Castelvecchio_Pascoli #Kedrion #Aceruloplasminemia

Kedrion's Commitment to Innovation and Patient Care at IPIC 2025 Kedrion Biopharma participates in IPIC 2025 focusing on secondary immunodeficiencies. The event offers insights into cutting-edge therapeutic advancements.

Kedrion's Commitment to Innovation and Patient Care at IPIC 2025 #Italy #Castelvecchio_Pascoli #Kedrion #Immunodeficiencies #IPIC_2025

Kedrion Pioneers Discussion on Secondary Immunodeficiencies at IPIC 2025 Kedrion Biopharma is leading the conversation on secondary immunodeficiencies at IPIC 2025, emphasizing patient care and innovative therapies.

Kedrion Pioneers Discussion on Secondary Immunodeficiencies at IPIC 2025 #Italy #Kedrion_Biopharma #Castelvecchio_Pascoli #Immunodeficiencies #IPIC_2025

Kedrion Biopharma Marks 2024 with 10% Growth and Brand Revamp Kedrion Biopharma showcases a significant 10% growth for 2024 along with the launch of its new brand identity aimed at enhancing patient therapy access.

Kedrion Biopharma Marks 2024 with 10% Growth and Brand Revamp #Italy #biopharmaceuticals #Kedrion_Biopharma #plasma-derived_therapies #Castelvecchio_Pascoli